Neutrophil-vascular interactions drive myeloperoxidase accumulation in the brain in Alzheimer’s disease

Leon C. D. Smyth1,2,3, Helen C. Murray4,5, Madison Hill1,2, Eve van Leeuwen1,2, Blake Hightet1,5, Nicholas J. Magon1,2, Mahyar Osanlouy6, Sophie N. Mathiesen7,8, Bruce Mockett7, Malvindar K. Singh-Bains4,5, Vanessa K. Morris9, Andrew N. Clarkson10, Maurice A. Curtis4,5, Wickliffe C. Abraham7, Stephanie M. Hughes8, Richard L. M. Faul2,5, Anthony J. Kettle1,2, Mike Dragunow4,11* and Mark B. Hampton1,2*

Abstract

Introduction: Neutrophil accumulation is a well-established feature of Alzheimer’s disease (AD) and has been linked to cognitive impairment by modulating disease-relevant neuroinflammatory and vascular pathways. Neutrophils express high levels of the oxidant-generating enzyme myeloperoxidase (MPO), however there has been controversy regarding the cellular source and localisation of MPO in the AD brain.

Materials and methods: We used immunostaining and immunoassays to quantify the accumulation of neutrophils in human AD tissue microarrays and in the brains of APP/PS1 mice. We also used multiplexed immunolabelling to define the presence of NETs in AD.

Results: There was an increase in neutrophils in AD brains as well as in the murine APP/PS1 model of AD. Indeed, MPO expression was almost exclusively confined to S100A8-positive neutrophils in both human AD and murine APP/PS1 brains. The vascular localisation of neutrophils in both human AD and mouse models of AD was striking and driven by enhanced neutrophil adhesion to small vessels. We also observed rare infiltrating neutrophils and deposits of MPO around plaques. Citrullinated histone H3, a marker of neutrophil extracellular traps (NETs), was also detected in human AD cases at these sites, indicating the presence of extracellular MPO in the vasculature. Finally, there was a reduction in the endothelial glycocalyx in AD that may be responsible for non-productive neutrophil adhesion to the vasculature.

Conclusion: Our report indicates that vascular changes may drive neutrophil adhesion and NETosis, and that neutrophil-derived MPO may lead to vascular oxidative stress and be a relevant therapeutic target in AD.

Keywords: Alzheimer’s disease, Neutrophil, Neutrophil extracellular trap, Blood–brain barrier, Myeloperoxidase

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
are beneficial, especially in containing infection, while in chronic sterile inflammation evidence suggests that off-target effects of neutrophil activation can contribute to tissue damage [2].

Alzheimer’s disease (AD) is a neurodegenerative disease characterised by the accumulation of amyloid plaques and tangles of hyperphosphorylated tau [3]. Interestingly, AD has a chronic neuroinflammatory component that drives neurodegeneration [4–6], and cerebrovascular inflammation is important in recruiting peripheral immune cells in other neuroinflammatory diseases [7, 8]. Neutrophil accumulation in AD has been well documented [9–12], but recent reports also indicate that neutrophils contribute to pathology and cognitive impairment in AD [9, 11–13], consistent with the idea that they play a deleterious role in chronic diseases [2]. Indeed, there is an amyloid-independent improvement in cognition in mouse AD models when neutrophils are depleted or when interactions between neutrophils and cell adhesion molecules in blood vessels are blocked [9, 11, 12]. There have been reports of both neutrophil infiltration [10, 11] and vascular localisation [12, 13], and recent studies have indicated that neutrophil plugging of capillaries reduces cerebral blood flow in both the APP/PS1 and 5XFAD models of AD to drive cognitive deficits [12, 13], although the localisation of neutrophils in human Alzheimer brains has not been analysed in any detail.

In order to infiltrate the brain, neutrophils must pass across the blood brain barrier (BBB), formed by brain endothelial cells. Under normal circumstances, circulating neutrophils flow through cerebral vessels. However, following an injury, inflammation triggers the expression of chemokines and adhesion molecules in cerebral vessels that recruit and promote the attachment of neutrophils to the vessel wall [14, 15]. Concurrently, the glycocalyx, a proteoglycan structure that prevents the interaction of surface molecules such as cell adhesion molecules, collapses, facilitating neutrophil attachment [16]. Once adhered to the vasculature, the interaction of endothelial membrane protrusions, containing multiple adhesion molecules, facilitate the migration of immune cells into the brain parenchyma [17].

The neutrophil oxidant-producing enzyme myeloperoxidase (MPO) has also been suggested to play a role in AD [9, 12, 18–21]. Adoptive transfer of bone marrow from Mpo−/− to 5XFAD mice reduces neuroinflammation, indicating a role for MPO-derived oxidants in AD-associated neuroinflammation [9]. While there is a consensus that MPO abundance is increased in AD, there are conflicting reports regarding its localisation and cellular source. MPO has been reported to localise to amyloid plaques [18, 20] and tau tangles [19], while the brain cells that have been reported to produce MPO include neurons [19], astrocytes [20], and microglia [19], as well as neutrophils [11]. The localisation and source of MPO has a profound impact on the targets of MPO-derived oxidants [22], especially because the major oxidant produced, hypochlorous acid (HOCl), is extremely reactive and has a limited diffusion radius [23].

In neutrophils, MPO is contained within cytoplasmic granules, and degranulation must occur before the enzyme is fully active. One way of enabling MPO release is the formation of neutrophil extracellular traps (NETs) in which mixing of chromatin and granule contents occurs, before the NET is expelled [24]. Once released, NETs are powerful activators of the immune response, forming a DNA–protein matrix decorated with damage-associated molecular patterns such as S100 proteins [25–27]. While infectious agents trigger NET formation [28], they have also been reported in sterile inflammatory diseases, including atherosclerosis and gall-stone formation [24, 29, 30]. There have been preliminary reports of NETosis in AD [11], however the abundance and localisation of the NETs have not yet been characterised.

We set out to investigate the accumulation and localisation of neutrophils in AD, as well as the source and distribution of MPO. We confirmed that there is neutrophil accumulation in AD, and demonstrated using a panel of antibodies that MPO was almost exclusively localised with other neutrophil markers. Strikingly, neutrophils accumulated throughout the vasculature in the AD brain, but only limited infiltration observed. We also observed rare deposits of MPO outside the vasculature, which were associated with plaques. To test whether plaque-associated MPO was present as NETs, we used a panel of antibodies to stain for potential NETosis, and while we did observe specific NET labelling these were only found in the vasculature. We also observed that there was a loss of endothelial glycocalyx staining in the AD vasculature, which may drive enhanced neutrophil-vascular interactions in AD.

Materials and methods

Human tissue

All post-mortem human brain tissue used in this study was obtained from the Neurological Foundation of New Zealand Human Brain Bank in the Centre for Brain Research, University of Auckland. All protocols in this study were approved by the University of Auckland Human Participants Ethics Committee (2008/279 and 011,654), and all families provided informed consent. All cases were examined by an independent neuropathologist and were classified based on neurological abnormalities, or lack thereof in neurologically normal control cases (Additional file 1: Table S1). Tissue microarrays
of AD and control tissue were generated from paraffin-embedded blocks as described previously [31, 32].

Animal models
APP/PS1 transgenic mice
APP/PS1 transgenic mice on a C57BL/6 J background were bred at Otago University, New Zealand, from stock imported from the Jackson Laboratory (APPswe, PSEN1ΔE9)85Dbo, MMRRC stock No: 34832-JAX). Non-litter matched transgenic (n = 12) and wild-type (n = 12) male mice were obtained by breeding hemizygous males with wild-type females. Animals were single group-housed in standard caging on a 12-h light/dark cycle, and food and water were available ad libitum. Ethical approval for the mouse work was obtained from the University of Otago Animal Ethics Committee (AUP-19–82). Mice were euthanised by transcardial perfusion with saline followed by 4% paraformaldehyde (PFA) at 4 and 12 months of age, and tissue fixed by perfusion in 4% paraformaldehyde (PFA) in 0.1 M phosphate buffer (PB) for 1 day, followed by 30% sucrose in PB for 2 days. In all experiments, male mice were used. Brains were stored in optimal cooling temperature mounting medium and were sectioned in the sagittal plane (40 μm thickness). Sections were stored in cryoprotectant solution containing 30% sucrose and 30% ethylene glycol in PB at – 20 °C for later use.

Stroke
All procedures were performed in accordance with the guidelines on the care and use of laboratory animals set out by the University of Otago, Animal Research Committee (AUP-19–160). Focal stroke was induced by photothermal injury in adult male C57BL/6J mice (3–4 months, 27–30 g) as previously described [33–35]. Under isoflurane anaesthesia (4% induction, 2–2.5% maintenance in air) equipped with MetaSystems VSlide slide scanner (MetaSystems) running MetaFer (V 3.12.1) with a 20 × objective, NA 0.50; Nikon, Japan) with large regions acquired by tiling. Massively multiplexed immunostaining
Using a protocol adapted from Maric et al. [36] and Murray et al. [37], paraffin-embedded tissue microarray sections of AD and normal middle temporal gyrus were processed as above. Imaging was carried out with an automated fluorescence microscope (Zeiss AxioImager) equipped with MetaSystems VSlide slide scanner (MetaSystems) running MetaFer (V 3.12.1) with a 20 × air objective (0.9 NA). This microscope is equipped with 6 custom excitation/dichroic/emission filter sets optimised for spectral separation of compatible fluorophores
as previously described (Maric et al. [36]). Antibodies were then stripped from sections with the addition of 5X NewBlot™ Nitro Stripping Buffer (Li-Cor, NE, USA) for 10 min at room temperature. Sections were then washed in PBS, epitope retrieval performed where necessary, and a subsequent round of immunostaining and imaging performed as above. This was completed over four rounds. Alignment of images from all four rounds was performed using a custom Python script [38]. We confirmed the effectiveness of stripping at removing previous antibodies in Additional file 1: Figure S5.

**Neutrophil isolation**

Venous blood was collected from healthy donors with informed consent under the ethical approval of the Southern Health and Disability Ethics Committee (Wellington, New Zealand [URA/06/12/083]). Neutrophils were isolated as previously described [39]. Briefly, dextran (1% (w/v)) sedimentation was followed by Ficoll density centrifugation, then hypotonic lysis to remove remaining red blood cells. Granulocytes were suspended in RPMI-1640 (Gibco, CA, USA) containing 2% FBS plus 10 mM HEPES. Purity was assessed by flow cytometry, and cultures were routinely >98% pure. Where relevant, serum was obtained from blood collected without anticoagulant and left to clot at room temperature. The clot was pelleted (1200×g; 2 min) and the serum was collected and stored on ice until required.

**Amyloid-β preparation**

Lyophilised Aβ1-42 (H1368, Bachem) peptide was resuspended in 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP; 105,228, Sigma) to 1 mM through the rubber septum using a 2.5 mL glass Hamilton syringe with a Teflon plunger and sharp needle and allowed to sit at room temperature for 30 min. Aβ1-42-HFIP solution was aliquoted into single-use lo-bind Eppendorf tubes and allowed to sit overnight in a fume hood to evaporate HFIP. To ensure complete removal, tubes were transferred to a SpeedVac and dried for 1 h at room temperature. The resulting peptide films were stored at −20 °C until use. To generate a monomeric preparation of Aβ1-42, the peptide film was allowed to come to room temperature, diluted to 5 mM in DMSO and sonicated for 10 min at room temperature. Aβ1-42 was further diluted in phenol-free DMEM (Gibco) to 100 μM and used immediately for the monomeric preparation. To generate oligomers, the monomeric preparation method was used, however, the resulting Aβ1-42 preparation was incubated at 4 °C for 24 h prior to use. To generate fibrils, the Aβ1-42 solution was diluted to 100 μM in 10 mM HCl and incubated at 37 °C for 24 h prior to use. To generate aggregates, Aβ1-42 was resuspended in sterile water at 500 μM, vortexed thoroughly, and stored in aliquots at −20 °C. In all instances Aβ1-42 was diluted to a final concentration of 1 μM in culture media.

**ELISA**

**MPO**

Myeloperoxidase abundance and activity was measured in clarified brain tissue lysates from the entorhinal cortex. Brain samples that had been snap frozen at -80 °C were placed in lysis buffer (25 mM Tris–HCl pH 7.5, 150 mM NaCl, 50 mM NaF, 0.5 mM EDTA pH 8, 0.5% Triton-X 100™, 5 mM β-glycerophosphate, with fresh 1 mM DTT, 1 mM PMSE, 1 mM Na3VO4) with 1 mm stainless steel beads and homogenised with a bead beater. The lysate was then spun at 14 000×g for 20 min, and the supernatant containing soluble protein taken. Samples were normalised to protein content in diluent (1% (w/v) bovine serum albumin (BSA) in PBS with 0.05% Tween-20 (v/v)). A high-binding 96 well plate was then coated in a mouse anti-MPO capture antibody (1:500 in PBS; clone 4A4, ThermoFisher) overnight at 4 °C. The following day, wells were blocked in diluent for 1 h at room temperature. Samples were added alongside an 8-point standard curve (0.7 – 50 ng/mL) of purified MPO, and left for 1 h at room temperature. AmplexRed assay buffer (50 μM AmplexRed, ThermoFisher; in 50 mM phosphate buffer with 50 mM NaBr and 20 μM H2O2) was added for 15 min, and fluorescence (ex 530 nm, Em 590 nm) was measured on a Synergy Neo2 HTS plate reader (BioTek, VT, USA). A rabbit polyclonal antibody to MPO (1:800 in diluent) was then added overnight at 4 °C. Biotinylated goat anti-rabbit secondary antibody (1:2000; Sigma, MO, USA) was added for 1 h at 37 °C, followed by ExtrAvidin alkaline phosphatase (1:1000; Sigma) for 1 h at room temperature. The alkaline phosphatase activity of samples was then measured from the conversion of p-nitrophenyl phosphate, with absorbance measured at 405 nm using a VarioSkan™ LUX microplate reader (ThermoFisher).

**Calprotectin**

The abundance of calprotectin was measured in samples using the commercially available CALPRO ELISA kit (Svar, Sweden) as per manufacturer’s instructions.

**Sytox green NETosis assay**

Acutely isolated neutrophils were seeded in RPMI-1640 with 2% FBS and 5 μM Sytox Green (ThermoFisher) at 100 000 cells/well in a 96 well plate. A control where Sytox Green was absent was included for background subtraction. Neutrophils stimulated with phorbol 12-myristate 13-acetate (20 nM, PMA; Sigma) were
used as a positive control. Neutrophils were treated with amyloid-β_{1-42} (1 μM, Aβ_{1-42}), with 10% (v/v) autologous donor serum, the monoclonal antibody against Aβ_{1-42} 4G8 (10 ng/mL), or vehicle (0.01% DMSO). Fluorescence (ex 460 nm, Em 516 nm) was measured every 5 min on a Synergy Neo2 HTS plate reader (BioTek, VT, USA).

**Thioflavin T assay**
Freshly prepared Aβ_{1-42} species or vehicles were added to PBS containing 20 mM thioflavin T (ThT). Samples were left at 37 °C for 1 h, then fluorescence (ex 440 nm, em 492 nm) measured with a VarioSkan™ LUX microplate reader.

**Negative-stain transmission electron microscopy**
Copper grids with 300 meshes coated with formvar/carbon film (ProSciTech, Australia) were floated on a 5 μl drop of a 50 μM Aβ_{1-42} protein sample and incubated for 60 s. Grids were washed once with water, and then floated on 5 μl of uranyl acetate solution (2% w/v) for 30 s. Micrographs were taken on a Philips CM200 200 kV transmission electron microscope equipped with a Gatan digital camera.

**Image analysis**
All automated image analysis was performed on CellProfiler (v4.0.7) using custom pipelines. The experimenters were blinded to the genotype and pathology of the patients in all cases.

**Neutrophil and NET abundance**
Neutrophils were thresholded based on intense staining for MPO and S100A8 following rolling ball background subtraction and smoothing. Large objects were excluded. NETs were identified as being positive for CitH3, S100A8, and MPO. A lectin mask was used to determine their localisation as vascular.

**Lectin intensity**
A low all-vessel threshold was performed following rolling ball background subtraction to include mid and low intensity vessels. Alternatively, collagen IV-positive vessels were identified with a high threshold. Large and small objects were filtered out. The size of objects was measured and segregated into ‘large’ and ‘small’ vessels based on the minor axis length cut-off of 12 μm (lectin) or 15 μm (collagen IV). The mean intensity within the large vessel and small vessel objects was then measured.

**MPO colocalisation/association**
MPO, S100A8, amyloid-β, and pTau positive structures were thresholded following rolling ball background subtraction. Objects that were touching were considered colocalised/associated.

**Vascular vs extravascular MPO**
A low all-vessel threshold was performed as above and dilated, then the MPO image masked by this. MPO-positive objects were then identified in the masked area (vasculature) and the unmasked area (parenchyma).

**Yang et al. database [40]**
Single-nuclear RNA-seq counts from the human AD vasculature were obtained from [https://twc-stanford.shinyapps.io/human_bbb/](https://twc-stanford.shinyapps.io/human_bbb/).

**Data analysis**
Data were analysed with GraphPad Prism (v 9.01). Data from larger TMA cohorts are presented as box-and-whisker, with the range, interquartile range, and median presented. Where outlier values were detected (>2 SD outside the mean), staining quality was inspected to ensure the validity of results and if artefacts were detected, the outlier was removed. Otherwise, the value was included. All other data are presented as mean ± standard error of mean. Appropriate statistical tests were carried out, following a test of the normality of data. Briefly, t-tests were performed where there were two groups, and two-way ANOVA where there were two factors. Multiple comparisons were performed with Tukey’s post-hoc test.

**Results**
Neutrophils accumulate in the human AD brain and APP/PS1 mouse model of AD
We initially used tissue microarrays to measure the accumulation of neutrophils in the human AD brain using a range of markers including three antibodies against MPO, as well as antibodies against CD66B, and S100A8. For all of these markers, small spherical cells were observed, with little apparently glial or neuronal immunoreactivity, indicating that, as expected, they were detecting neutrophils (Fig. 1a-e). Additionally, cells stained for these antibodies had polymorphic nuclei, indicating that the cells they stained were indeed neutrophils (Additional file 1: Fig. S1). We found that there was a consistent increase in the abundance of these neutrophils within AD brains, as measured by all MPO antibodies, as well as antibodies against S100A8 and CD66B (Fig. 1a-e). Although other
studies have detected S100A8 in other cell types [41], in our hands it was a reliable marker for neutrophils. In order to stain murine AD model brains, we tested a range of antibodies but found that only AF3667 gave specific signal in positive control stroke tissue (Additional file 1: Fig. S1). Analysis of neutrophil density by sex, age, and post-mortem delay revealed neutrophil accumulation was independent of these covariates, although we observed somewhat greater variability in males (Additional file 1: Fig. S2). We immunolabelled MPO and S100A8 in the APP/PS1 mouse model, which has previously been shown to have cerebral neutrophil
accumulation, and we observed an increase in neutrophil abundance in the cortex of both 4 and 12-month-old mice, although this was less striking than in human specimens (Fig. 1f, g). Regional analysis of mouse brains indicated that this effect was strongest in the cortex and hippocampus, although similar trends were observed in brainstem and cerebellum (Additional file 1: Fig. S3). Cortical and hippocampal densities were similar, and neutrophil accumulation in these regions was therefore quantified together. Finally, we observed an increase in the abundance of neutrophil markers calprotectin, of which S100A8 is a subunit, and MPO in AD brains by ELISA (Fig. 1h-j).

MPO accumulation in the AD brain is driven by an increase in vascular neutrophils
Because we mainly observed neutrophil-like MPO staining in brain tissue, we wanted to determine if neutrophil abundance was the major factor driving the increase in MPO found in AD [18–20]. We therefore used alternative neutrophil markers calprotectin and S100A8 in immunostaining and ELISA, and found that these were positively correlated with MPO abundance (Fig. 2a, b). Indeed, in immunolabelling experiments at least 97% of MPO-positive cells were co-labelled with S100A8 (Fig. 2c). Previous reports have suggested that neutrophil accumulation in mouse AD models occurs primarily in the vasculature [12], and we therefore wished to determine the localisation of neutrophils relative to blood vessels. We used tissue microarrays to measure MPO localisation within the human AD brain and found that neutrophils were present in higher numbers in the human AD vasculature (Fig. 2d, e). Interestingly, when we compared the localisation of neutrophils by vessel segment, we observed that there were increases in both large and small vessels, however the magnitude of increase was greater in small vessels (< 12 μm diameter; Fig. 2d, e). In both control and AD brains we found that the majority of MPO labelling was contained in blood vessels (Fig. 2f).

Interestingly, we also observed the presence of the BBB leakage product hemoglobin in close proximity to neutrophils found within blood vessels (Fig. 2g). In mouse AD model brains, we found a similarly striking vascular localisation of neutrophils in APP/PS1 mouse brains (Fig. 2h), as has been described previously [12]. Although the majority of neutrophils were found in the vasculature, we did observe rare extravascular CD66B-positive neutrophils indicating that infiltration does occur, albeit at a low rate (Fig. 3a, b). Furthermore, we observed sporadic deposition of MPO localised to amyloid plaques and tau tangles (Fig. 3a-d). Indeed, approximately half of the extravascular MPO-positive structures were localised to plaques, and a quarter to tangles (Fig. 3a, e). We observed significant correlations between both amyloid and tau deposition and MPO accumulation, although this was stronger for amyloid than tau (Fig. 3f, g).

**NETosis occurs in the AD vasculature**
The formation of NETs is an important neutrophil effector function, and has been linked to vascular remodelling in the retina as well as stroke and traumatic brain injury [42–44]. We initially hypothesised that NETs would be present in the AD vasculature and MPO deposits around plaques in the brain. We used massively multiplexed immunolabelling of brains to stain a panel of pathological (Aβ, tau, NeuN), inflammatory (Iba1, L-ferritin, HLA-DR, GFAP), vascular (Lectin, Collagen IV, hemoglobin), and neutrophil markers (MPO, S100A8), alongside the specific NET marker CitH3 to categorically define NETs (Fig. 4a). We confirmed the specificity of the CitH3 antibody in brain tissue, detecting NETs in a murine model of stroke (Additional file 1: Fig. S1). We observed the presence of CitH3 exclusively localised to neutrophil markers, however only a sub-population of neutrophils was detected, indicating that it was indeed labelling NETs (Fig. 4b). We hypothesised that, analogous to their response to other large aggregated structures such...
Fig. 2 (See legend on previous page.)
as gallstones and cholesterol crystals, neutrophils may respond to aggregated forms of Aβ1-42 through NET formation [29, 30]. However, we did not detect NETosis in response to Aβ1-42 in any aggregation state in vitro (Additional file 1: Fig. S4). Furthermore, we only observed CitH3 localised to vascular neutrophils (Fig. 4b, f), but not plaque associated MPO-deposits as we originally hypothesised. MPO in these regions was colocalised with activated microglial markers Iba1, L-ferritin, and HLA-DR (Fig. 4c). Although NETs were present at higher levels in AD, they were only present in low abundance and in less than half of the cohort (Fig. 4d-g).

Reduced endothelial glyocalyx in AD vessels

During previous experiments (Figs. 2, 3, 4), we observed a reduction in the intensity of staining for UEAI lectin, a marker for fucosylation in the glyocalyx, in human AD vessels. Indeed, image analysis indicated that there was a significant decrease in UEAI staining intensity in AD, irrespective of vessel size (Fig. 5a, b). To ensure results were not confounded by changes to vascular density, we used collagen IV as a total vascular marker, and measured lectin intensity within collagen-positive structures, again segregating large and small vessels. There was a similar reduction in the lectin staining, particularly in small vessels, however a similar trend was observed in large vessels too (Fig. 5a, b). We also interrogated potential mechanisms through which attachment may be mediated using a single-cell RNAseq atlas of the AD vasculature [40]. Interestingly, although there were no increases in the expression of cell adhesion molecules (ICAM1, ICAM2, VCAM1, SELE) in endothelial cells, there was a decrease in FUT11, an enzyme associated with the production of the glyocalyx (Fig. 5c, d) [40].

Discussion

While increased MPO [11, 18–20] and cerebral neutrophil accumulation [10–13] are well-established features of AD, there have been several reports of unusual cellular sources and localisations of MPO. Previous reports have primarily focussed on the accumulation of neutrophils in mouse models [10–13], or have used a limited panel of antibodies [11, 18, 19]. We used tissue from a large human cohort and mouse tissue to show that MPO deposition in the AD brain is primarily driven by neutrophil accumulation. The majority of this MPO is contained in vascular-associated neutrophils, confirming reports from animal models of AD [12]. Furthermore, we find evidence for vascular NETosis in human AD. Finally, we observe a decrease in staining for the glyocalyx using UEAI lectin to indicate that reductions in the endothelial glyocalyx may drive neutrophil accumulation in the AD vasculature.

Several reports have indicated that MPO may be produced by non-neutrophil cells, including microglia [19], astrocytes [20], and neurons [19]. Using multiple different antibodies we confirmed that the majority of MPO staining was confined to neutrophils. It should be noted that, although S100A8 can be expressed in other cell types, MPO was also found almost exclusively colocalized with other neutrophil markers including CD66B. Furthermore the nuclei associated with MPO were polymorphonuclear. We did, however, observe low levels of MPO in plaque-associated microglia, reinforcing reports that it may be a microglial activation marker [46]. Since the bulk of MPO labelling was confined to neutrophils, we concluded that the increase of MPO in AD is mainly driven by the accumulation of neutrophils in the brain. Strikingly, we predominantly observed neutrophils present within lectin-positive blood vessels, and only very rarely in the parenchyma in both a mouse model of amyloidosis and in human AD.

Our work corroborates findings from mouse AD models in human AD, suggesting that neutrophil plugging of capillaries leads to blood flow reductions in AD [12, 13]. Importantly, neutrophil plugging of the vasculature occurred early in this mouse model, and the removal of neutrophil plugs led to improved cerebral blood flow and cognition [12, 13]. While our work was performed on tissue from end-stage disease, this suggests that neutrophil plugging may also be present early in human AD. The enhanced neutrophil-vascular interactions observed in AD suggest that either neutrophils or the vasculature become ‘stickier’. It is also important to note that human samples are processed differently to those in mouse studies, with a significant delay between death and perfusion-fixation, and this may influence the numbers of neutrophils present in the vasculature. Despite this, tissue processing is consistent between human samples, and so results remain internally consistent.

There have been conflicting reports, some suggesting that the cell adhesion molecules ICAM1 and VCAM1...
Fig. 3 (See legend on previous page.)
are enhanced in the AD vasculature [11, 47], but more recent findings indicate that expression of genes involved in neutrophil attachment are unchanged in human AD endothelia [40]. Interestingly, although vascular neutrophils were increased in APP/PS1 mice, the degree of attachment was lower than in AD, suggesting that although vascular changes are present, they are not equivalent [40]. Furthermore, we find that UEA-1 lectin staining of the endothelial glycocalyx is decreased in AD. Indeed, loss of endothelial glycocalyx in a mouse model of subcortical vascular dementia was responsible for capillary stalling [48]. Furthermore, hyaluronan, a marker of glycocalyx damage, was elevated in the cerebrospinal fluid of AD and vascular dementia patients [49, 50]. Circulating neutrophils have been reported to be more activated in AD [51], and they can also alter the endothelial glycocalyx [52, 53], so it is possible that these changes to neutrophil activation state are responsible for glycocalyx changes and vascular attachment. However, we speculate that glycocalyx thinning may result from reduced production with reduced expression of FLIT1, a gene involved in glycocalyx production in AD endothelial cells [40]. This may allow for enhanced neutrophil attachment, even in the absence of strong cell adhesion molecule expression. Furthermore, in the absence of strong cell adhesion molecule expression, attachment would not facilitate neutrophil infiltration, and may explain why neutrophils remain in the vasculature. In human samples though, it is worth noting that we could not distinguish the means through which neutrophils had become present in vessels. Indeed, it is possible that the observed accumulation of neutrophils here may have been the result of them becoming trapped, rather than adhering the vessel wall. Importantly, although human and mouse brains were processed differently, we did observe similar enhancement of vascular associated neutrophils in AD and the APP/PS1 mouse model of AD indicating that our observations are unlikely to be the result of a post-mortem artefact. It will be important to further validate changes to the AD glycocalyx composition, and the expression of the enzymes that synthesise it. Indeed, it may be possible to modify endothelial glycocalyx synthesis to prevent neutrophil adhesion to capillaries in AD.

The accumulation of neutrophils and MPO in the brain vasculature has important consequences for the surrounding cells [22]. Indeed, cells at the borders of the brain can have profound effects on cognition and pathology. MPO binds strongly to the vascular endothelium through its interactions with the negatively charged glycocalyx in other chronic inflammatory diseases, including heart disease, to cause endothelial dysfunction [52, 54, 55]. Here, too, we observe BBB dysfunction at sites where neutrophils are attached to blood vessels. Furthermore, MPO impairs the barrier function of brain endothelial cells through the production of HOCl [56]. HOCl is highly reactive and consumed close to its site of production [23]. It is possible that longer-lived secondary oxidants such as chloramines mediate the effects of HOCl on the vasculature [23]. In the presence of thiocyanate concentrations present in plasma, MPO also generates HOSCN [57]. We have found that this longer lived, thiol-selective oxidant can impact endothelial cells at sub-lethal doses [58], including disruption of BBB function [59]. In the context of AD, it is possible that neutrophil-vascular interactions are an important mechanism through which BBB dysfunction is established [22].

We observed very little parenchymal MPO indicating that the majority of neutrophil attachment in AD does not lead to neutrophil infiltration. However, it is clear that there is a limited degree of neutrophil infiltration into the AD brain, supporting previous reports [10, 11]. It is interesting to note that we did not observe profound infiltration of neutrophils into the brains of APP/PS1 mice. While this contradicts results in tauropathy and 5XFAD mice, it does align with other reports from the APP/PS1 model, indicating that strain may influence the infiltration of neutrophils in AD models [12]. Furthermore, we detected parenchymal MPO deposits associated with AD pathology. These MPO deposits were larger and morphologically different to staining patterns observed in neutrophils. When activated, neutrophils are capable of forming NETs, creating a DNA–protein matrix that has powerful immunostimulatory properties [28]. We initially hypothesised that these MPO deposits were NETs however we could not observe colocalisation of other neutrophil or NET markers. Plaque-associated MPO deposits were colocalised with markers of activated microglia (HLA-DR, L-ferritin), albeit at much lower levels than neutrophils. Indeed, MPO may be an activation marker in microglia in its own right [46]. It is
Fig. 4 (See legend on previous page.)
Fig. 5 Reduction in endothelial glycocalyx in AD brain. AD tissue microarrays from the middle temporal gyrus (N = 21–37 per condition) were labelled for the total vessel marker collagen IV, and endothelial glycocalyx marker UEA1 lectin. a Representative images of lectin immunolabelling, and b quantification of lectin intensity in blood vessels in control and AD brains, segregated by vessel size. Scale = 250 μm. P-values represent results of an two-way ANOVA. Single nuclear RNA-seq from the human AD vasculature were obtained from https://twc-stanford.shinyapps.io/human_bbb/, and genes involved in c cell adhesion processes, and d fucosylation of the endothelial glycocalyx evaluated.
also possible that parenchymal NETs cannot be detected through CitH3 labelling, as the citrullination occurs in a region of the histone tail that is cleaved during NETosis and is a more robust marker of early, rather than mature, NETs [60]. Antibodies to NET-specific modifications in mature NETs could be used to detect this phenomenon [60].

We observed NETosis in the AD vasculature, although this was not ubiquitous and the presence of NETs was rarer than in stroke, our positive control. There have been other reports of NETosis in sterile neurological diseases, including stroke and traumatic brain injury, where they are involved in vascular remodelling [42, 43]. While there are preliminary reports of NETosis in the AD brain [11], their localisation has not been interrogated. Recent reports indicate that senescent endothelial cells attract and promote NETosis to trigger vascular remodelling in the retina following oxygen-induced retinopathy [44], and that NETs also play a role in vascular remodelling following stroke [43]. It is possible that a similar phenomenon occurs in AD, leading to vascular regression [40, 61]. Recent reports suggest that CNS-associated neutrophils are derived from multiple sources, including the blood and adjacent skull bone marrow [62, 63]. The vascular association of neutrophils observed here suggests their origin from the circulation, which may be associated with activated neutrophil phenotypes in AD that are more prone to NETosis [62].

The localisation of neutrophils and MPO within cerebral vessels suggests that they may be a peripheral target with the potential to enhance cognitive function in AD. Indeed, preventing leukocyte tethering to the brain vasculature improves cognition in aging [64], as well as in models of AD [11– 13]. Furthermore, the presence of NETs, and therefore extracellular MPO at the brain vasculature represents a novel AD-associated process. It may be possible to prevent MPO release by targeting NETosis, degrading NETs, or by addition of molecules that sequester MPO from the glycocalyx to ‘wash’ it off the endothelium without modulating potentially beneficial functions within the neutrophil cytoplasm [57,66]. Although the majority of neutrophils in AD are present at a brain barrier and not within the brain itself, they may still have important effects on cognition [9, 11, 12], so targeting inflammation in BBB endothelial cells or through modulation of neutrophils may be a useful therapeutic target in AD [15].

Conclusions

Here, we confirm data from animal models in the human AD brain suggesting that neutrophils accumulate, and are associated with blood vessels in AD where they may contribute to vascular stalling and BBB leakage (Fig. 6). We also show that neutrophils and NETs are the key source of MPO in the brain during AD which may represent an important mechanism through which BBB inflammation influences oxidative stress in AD.

Abbreviations

Aβ: Amyloid beta; AD: Alzheimer’s disease; APP/PS1: Amyloid precursor protein/presenilin-1 mouse AD model; BBB: Blood–brain barrier, CitH3: Citrullinated histone H3; ELISA: Enzyme-linked immunosorbent assay; FUT11: Fusosyltransferase 11; GFAP: Glial fibrillary acid protein; HLA-DR: Human Leukocyte Antigen–DR isotype; HOCl: Hypochlorous acid; HOSCN: Hypothiocyanous acid; Iba1: Allograft inflammatory factor 1; ICAM1: Intercellular cell adhesion molecule-1; NET: Neutrophil extracellular trap; S100A8: S100 calcium-binding protein A8; SELE: Selectin-endothelial; UEA-1: Ulex europaeus Agglutinin-1; VCAM1: Vascular cell adhesion molecule-1.
Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s40478-022-01347-2.

Additional file 1. Figure S1: MPO labelling is predominantly confined to neutrophils. Figure S2: Neutrophil accumulation is independent of sex, age, and post-mortem delay. Figure S3: Regional analysis of neutrophil accumulation in APP/PS1 mice. Figure S4: Amyloid-b1-42 does not induce NETosis in vitro. Figure S5: Specificity of antibody labelling across multiple rounds of multiplexed immunohistochemistry. Table S1: Case details of tissue used in tissue microarray and immunohistochemistry experiments. Table S2: Details of antibodies used for these studies.

Acknowledgements

We would like to thank the donors for their generous gift of brain tissue for research. We also thank staff at Auckland Hospital, the Neurological Foundation of New Zealand Human Brain Bank, and Sheryl Feng and Marika Eszes. We would like to thank Ms Emma Gowing for technical support for the stroke surgeries and preparing the tissues samples for processing. We also thank Dr Ursula Byrne for her studies on the role of MPO in Alzheimer’s disease. Mice were originally obtained from Mutant Mouse Regional Resource Centers and bred at the Biomedical Research Facility, University of Otago, New Zealand.

Authors’ contributions

LCDS wrote the manuscript. LCDS, HCM, AJK, MD, and MBH designed the experiments. LCDS performed the majority of experiments. HCM, MH, EvL, BAH, and NJM performed experiments. Alignment of multiplexed images was performed by MO and HCM. AANC performed the stroke surgeries. SNM, BM, SMH, VKM, ANC, MAC, WCA, RLME, MD, MKSB, and MBH all contributed materials and relevant expertise, and assisted in the manuscript preparation. All authors have read and approved the final manuscript.

Funding

We acknowledge the following funding bodies for their support of this research: the Health Research Council of New Zealand (15/479, 16/597, 21/710), the Hugh Green Foundation, and Brain Research New Zealand. Dr Leon Smyth was funded by a Neurological Foundation Philip Wrightson Postdoctoral Fellowship (1846WF). The ImageXpress Pico was partially funded by the Neurological Foundation Philip Wrightson Postdoctoral Fellowship. Animal costs for the study were supported by Brain Research New Zealand and performance-based research funding from the Department of Anatomy University of Otago (ANC). Sophie Mathiesen was funded by a PhD scholarship from Brain Research New Zealand.

Availability of data and materials

The data presented in this study are included in the manuscript and supplementary material. Additional data that are not included can be made available upon reasonable request to the corresponding author.

Declarations

Ethics approval and consent to participate

All human brain tissue protocols in this study were approved by the University in St. Louis, Campus, Box 8118, St. Louis, MO, USA. 4 Centre for Brain Research, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand. 5 Department of Anatomy With Medical Imaging, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.

Received: 9 February 2022  Accepted: 11 March 2022

Published online: 24 March 2022

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

1 Centre for Free Radical Research, University of Otago, Christchurch, New Zealand. 2 Department of Pathology and Biomedical Science, University of Otago, PO Box 4345, Christchurch 8140, New Zealand. 3 Department of Pathology and Immunology, Center for Brain Immunology and Glia, Washington University in St. Louis, Campus, Box 8118, St. Louis, MO, USA. 4 Centre for Brain Research, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand. 5 Department of Anatomy With Medical Imaging, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand. 6 Auckland Bioengineering Institute, University of Auckland, Auckland, New Zealand. 7 Department of Psychology, University of Otago, Dunedin, New Zealand. 8 Department of Biochemistry, University of Otago, Dunedin, New Zealand. 9 School of Biological Science, University of Canterbury, Canterbury, New Zealand. 10 Department of Anatomy, University of Otago, Dunedin, New Zealand. 11 Department of Pharmacology and Clinical Pharmacology, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.

References

1. Kolaczkowska E, Kubes P (2013) Neutrophil recruitment and function in health and inflammation. Nat Rev Immunol, pp 159–175
2. Soehnlein O, Steffens S, Hidalgo A, Weber C (2017) Neutrophils as protag‑onists and targets in chronic inflammation. Nat Rev Immunol 17:248–261
3. Masters CL, Bateman R, Blennow K, Rowe CC, Sperling RA, Cummings JL (2015) Alzheimer’s disease. Nat Rev Dis Prim, pp 1–18
4. Swanson MEV, Scotter EL, Smyth LCD, Murray HC, Ryan B, Turner C, et al (2020) Identification of a dysfunctional microglial population in human Alzheimer’s disease cortex using novel single-cell histology image analysis. Acta Neuropathol Commun, 8
5. Rustenhoven J, Smith AM, Smyth LC, Jansson D, Scotter EL, Swanson MEV et al (2018) PU1 regulates Alzheimer’s disease-associated genes in primary human microglia. Mol Neurodegener 13:44
6. Keren-Shaul H, Spinrad A, Weiner A, Matcovitch-Natan O, Dvir-Sternfeld R, Ulland TK et al (2017) A unique microglia type associated with restricting development of Alzheimer’s disease. Cell 169:1276-1290.e17
7. Smyth LCD, Rustenhoven J, Park Ti-H, Schweder P, Jansson D, Heppner PA et al (2018) Unique and shared inflammatory profiles of human brain endothelia and pericytes. J Neuroinflammation 15:138
8. Rustenhoven J, Jansson D, Smyth LC, Dragonow M (2017) Brain peri‑cytes as mediators of neuroinflammation. Trends Pharmacol Sci 38
9. Volkman R, Ben-Zur T, Kahana A, Garty BZ, Offen D (2019) Myeloperoxidase deficiency inhibits cognitive decline in the SXFAD mouse model of Alzheimer’s disease. Front Neurosci 13:990
10. Baik SH, Cha M-Y, Hyun Y-M, Cho H, Hamza B, Kim DK et al (2014) Migration of neutrophils targeting amyloid plaques in Alzheimer’s disease mouse model. Neurobiol Aging 35:1286–1292
11. Zenaro E, Pietronigro E, Bianca VD, Marongiu L, Budui S et al (2015) Neutrophils promote Alzheimer’s disease-like pathology and cognitive decline via LPA-1 integrin. Nat Med 21:880–886
12. Cruz Hernández JC, Bracko O, Kersbergen CJ, Muse V, Haft-Javaherian M, Berg M et al (2019) Neutrophil adhesion in brain capillaries reduces cortical blood flow and impairs memory function in Alzheimer’s disease mouse models. Nat Neurosci 22:413–420. https://doi.org/10.1038/s41593-018-0329-4
13. Bracko O, NJiru BN, Swallow M, Ali M, Haft-Javaherian M, Schaffer CB (2019) Increasing cerebral blood flow improves cognition into late stages in Alzheimer’s disease mice. J Cereb Blood Flow Metab. https://doi.org/10.1177/0271678X19873658
54. Rudolph TK, Rudolph V, Witte A, Klinsky A, Szoeck K, Lau D et al (2010) Liberation of vessel adherent myeloperoxidase by enoxaparin improves endothelial function. Int J Cardiol 140:42–47
55. Ullenh A, Singewald E, Konya V, Fauler G, Reicher H, Nusshold C, et al (2013) Myeloperoxidase-derived oxidants induce blood-brain barrier dysfunction in vitro and in vivo. PlaS OnE 8
56. van Dalen CJ, Whitehouse MW, Winterbourn CC, Kettle AJ (1997) Thiocyanate and chloride as competing substrates for myeloperoxidase. Biochem J 327:487–492
57. Bozonet SM, Scott-Thomas AP, Nagy P, Vissers MCM (2010) Hypothiocyanous acid is a potent inhibitor of apoptosis and caspase 3 activation in endothelial cells. Free Radical Biol Med 49:1054–1063
58. Tilley DO, Abuabed U, Zimny-Arndt U, Schmid M, Florian S, Jungblut R, et al (2021) Histone H3 clipping is a novel signature of human neutrophil. bioRxiv. doi: https://doi.org/10.1101/2021.03.15.434949
59. van Leeuwen E, Hampton MB, Smyth LCD (2022) Hypothiocyanous Acid Disrupts the Barrier Function of Brain Endothelial Cells. Antioxidants 11 (in revision)
60. Halliday MR, Rege SV, Ma Q, Zhao Z, Miller CA, Winkler EA et al (2016) Accelerated pericyte degeneration and blood–brain barrier breakdown in apolipoprotein E4 carriers with Alzheimer’s disease. J Cereb Blood Flow Metab 36:216–227. https://doi.org/10.1038/jcbfm.2015.44
61. Cugurra A, Mamladze T, Rustenhoven J, Dykstra T, Beroshvili G, Greenberg ZJ et al (2021) Skull and vertebral bone marrow are myeloid cell reservoirs for the meninges and CNS parenchyma. Science. https://doi.org/10.1126/science.aba7844
62. Herisson F, Frodermann V, Courties G, Rohde D, Sun Y, Vandooorne K et al (2018) Direct vascular channels connect skull bone marrow and the brain surface enabling myeloid cell migration. Nat Neurosci 21:1209–1217
63. Yousef H, Czupalla CJ, Lee D, Chen MB, Burke AN, Zera KA et al (2019) Aged blood impairs hippocampal neural precursor activity and activates microglia via brain endothelial cell VCAM-1. Nat Med 25:988–1000
64. Parka H, Albrett AM, Kettle AJ, Winterbourn CC (2012) Myeloperoxidase associated with neutrophil extracellular traps is active and mediates bacterial killing in the presence of hydrogen peroxide. J Leukoc Biol 91:369–376. https://doi.org/10.1189/jlb.0711387

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.